Studies on the promotion of nickel—alumina coprecipitated catalysts: I. Titanium oxide

A series of TiO2-promoted nickel—alumina catalysts has been prepared and characterized. The promoter was added in various proportions to a calcined coprecipitated nickel—alumina material by adsorption of the acetylacetonate complex of titanium, followed by further calcination and reduction. The structure of the resultant materials was similar to that of the unpromoted coprecipitated nickel—alumina. The chemisorption properties of the catalyst and its behaviour in the CO/H2 reaction were characteristic of a strong metal-support interaction (SMSI) reported in the literature for Ni/TiO2. The strong adsorption of both carbon monoxide and hydrogen were suppressed while the activity for carbon monoxide hydrogenation was increased, the activation energy being lowered. The higher activity, however, was relatively unstable under reaction conditions

Direct carrier detection by in situ suppression hybridization with cosmid clones of the Duchenne/Becker muscular dystrophy locus

A basic problem in genetic counseling of families with Duchenne/Becker muscular dystrophy (DMD/BMD) concerns the carrier status of female relatives of an affected male. In about 60% of these patients, deletions of one or more exons of the dystrophin gene can be identified. These deletions preferentially include exon 45, which can be detected by multiplex polymerase chain reaction (PCR) and Southern blot analysis of genomic cosmid clones that map to this critical region. As a new approach for definitive carrier detection, we have performed chromosomal in situ suppression (CISS) hybridization with these cosmid clones in female relatives of four unrelated patients. In normal females, most metaphases showed signals on both×chromosomes, whereas only one×chromosome was labeled in carriers. Our results demonstrate that CISS hybridization can define the carrier status in female relatives of DMD patients exhibiting a deletion in the dystrophin gene

Structure and reactivity of titania-supported oxides. Part 1: vanadium oxide on titania in the sub- and super-monolayer regions

Vanadium oxide has been deposited on TiO2 (washed anatase, 10 m2g−1; Degussa P-25, 55 ±3 m2g−1; Eurotitania, 46 m2g−1) by aqueous impregnation of (NH4)2[VO(C2O4)2] and by reaction with VOCl3, VO(OR)3 (R=iBu) and VO(acac)2 in organic solvents. Single applications of the last tree reagents form not more than a monolayer of vanadium oxide VOx, a monolayer being defined as 0.10 wt.% V2O5 per m2 of surface. When less than about four monolayers of VOx are present, there is in most cases only a single TPR peak: Tmax values, which increase with V2O5 content, are almost independent of the method used but vary slightly with the support (P-25 < Eurotitania < washed anatase). The 995 cm−1 band, characteristic of V&z.dbnd;O in V2O5, only appears when more than a monolayer of VOx is present.\ud \ud In the sub-monolayer region, VOx is best formulated as an oxohydroxy species bonded to two surface oxygens. As the V2O5 content is increased, layers of disordered V2O5 are formed on limited areas of the surface, but crystalline V2O5 only occurs, probably on top of the disordered V2O5, when the V2O5 content exceeds about four monolayers, and takes the form of acicular crystals exposing only planes perpendicular to the a and b axes

Glutathione S-transferase activity and isoenzyme composition in benign ovarian tumours, untreated malignant ovarian tumours, and malignant ovarian tumours after platinum/cyclophosphamide chemotherapy.

Glutathione S-transferase (GST) isoenzyme composition, isoenzyme quantities and enzymatic activity were investigated in benign (n = 4) ovarian tumours and malignant ovarian tumours, before (n = 20) and after (n = 16) chemotherapy. Enzymatic activity of GST in cytosols was measured by determining 1-chloro-2,4-dinitrobenzene conjugation with glutathione, cytosolic GST subunits were determined by wide pore reversed phase HPLC, using a S-hexylglutathione-agarose affinity column, and isoelectric focussing. Both GST activity and GST pi amount were not related to histopathologic type, differentiation grade, or tumour volume index in untreated malignant tumours. GST isoenzyme patterns were identical in benign tumours and malignant tumours before and after platinum/cyclophosphamide chemotherapy, while GST pi was the predominant transferase. Mean GST activity and GST pi amount were decreased (P < 0.05) in malignant ovarian tumours after platinum/cyclophosphamide chemotherapy compared to untreated ovarian malignant tumours. No relation was found in untreated ovarian tumours between GST pi amount and response to platinum/cyclophosphamide chemotherapy. Thus, within the limitations of the current study no arguments were found for a role of GST in in vivo drug resistance of malignant ovarian tumours to platinum/cyclophosphamide chemotherapy

CFD-DEM simulation of nanoparticle agglomerates fluidization with a micro- jet

Nanoparticles can be fluidized as agglomerates, but for some materials this is cumbersome due to the cohesive nature. Micro-jets are shown to be effective for improving the fluidization in such cases (1). In this study, the mechanisms of micro-jet assistance are investigated by using an adhesive CFD-DEM (Computational Fluid Dynamics – Discrete Element Modelling) model. In previous studies, the complex agglomerates found in a fluidized bed are treated as the discrete elements (2). Here we use the simple agglomerates as the discrete elements, which are the building blocks of the larger complex agglomerates. The collision of the simple agglomerates are modeled by including collision mechanisms of elastic-plastic, cohesive and viscoelastic forces. Particles with =40 and =250 are used to represent the simple agglomerates. The cohesive force is expressed by the non-dimensional parameter , definded by the ratio of der Waals force over the particle gravity. A fluidized bed with dimension of 3 mm × 0.4 mm × 12 mm containing ~120,000 particles is simulated. At different cases, a micro-jet with horizontal cross-section size of 20 x 20 pointing downwards is turned ON or OFF (36 m/s) while the gas velocity to the bed is set as 2.8 cm/s or 4 cm/s, respectively. The schematic of the microjet in the bed is shown in Figure 1. In this way, like in our previous study, we keep the total amount of gas provided to the bed equal (2). Please click Additional Files below to see the full abstract

Confirmation of Clinical Diagnosis in Requests for Prenatal Prediction of SMA Type I

The recent discovery of a major SMA-locus in the chromosomal region 5q makes it possible to carry out prenatal DNA studies in families in which a child with SMA type I has been born. Since direct mutation analysis is not yet possible, the reliability of prenatal prediction of SMA type I usually depends on the certainty of the clinical diagnosis in the index patient. Sixteen requests were received for DNA studies in couples who had had a previous child with SMA type I. After re-evaluation, the performance of prenatal diagnosis was rejected in four cases. Among the other twelve families prenatal DNA analysis of chorion villus biopsies has been carried out in three families. In all three cases the fetus had inherited the high-risk haplotypes from both parents, and the parents chose to terminate the pregnancy. An illustration of the prenatal DNA studies in one family is given. The importance of confirmation of the diagnosis SMA type I before performing DNA studies is emphasised

Screening for BRCA2 mutations in 81 Dutch breast–ovarian cancer families

We have analysed 81 families with a history of breast and/or ovarian cancer for the presence of germline mutations in BRCA2 with a number of different mutation screening techniques. The protein truncation test (PTT) for exons 10 and 11 detected four different frame-shifting mutations in six of these families. Four of the remaining 75 families had given positive linkage evidence for being due to BRCA2. In these families the entire coding region was analysed by single-strand conformational polymorphism, leading to the detection of a non-sense and a splice-site mutation in two of them. While these studies were in progress, Southern analysis of BRCA1 revealed that in our study-population of 81 families, 15 families were segregating either the exon 13 or exon 22 deletion in BRCA1 (Petrij-Bosch et al (1997) Nat Genet17: 341–345). This prompted us to examine BRCA2 in the remaining 58 families by Southern analysis, using two different restriction enzymes. No aberrations were found in the restriction patterns. Thus, contrary to BRCA1, large genomic rearrangements within the BRCA2 gene do not represent a major mutation mechanism among Dutch breast cancer families. © 2000 Cancer Research Campaig